Evaxion Biotech AS (EVAX)
2.59
-0.08
(-3.00%)
USD |
NASDAQ |
Nov 01, 16:00
Evaxion Biotech Debt to Equity Ratio: 6.720 for June 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2024 | 6.720 |
| March 31, 2024 | 0.00 |
| Date | Value |
|---|---|
| December 31, 2023 | -1.825 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-1.825
Minimum
Dec 2023
6.720
Maximum
Jun 2024
1.632
Average
--
Median
Mar 2024
Debt to Equity Ratio Benchmarks
| Ascendis Pharma AS | -2.095 |
| Novo Nordisk AS | 0.5071 |
| DBV Technologies SA | -- |
| Adaptimmune Therapeutics PLC | 0.2592 |
| Akari Therapeutics PLC | -- |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 15.23M |
| Total Liabilities (Quarterly) | 13.98M |
| Shareholders Equity (Quarterly) | 1.253M |
| Current Ratio | 2.800 |